Industry Overview - The traditional Chinese medicine (TCM) sector showed a decline of 0.32% last week, underperforming compared to the overall pharmaceutical sector which rose by 1.4% [2][3] - The TCM sector's PE (ttm) was 27.68X, down 0.1X week-on-week, while the PB (lf) was 2.29X, down 0.01X week-on-week [4] - The market for TCM raw materials is under pressure, with a total price index of 241.57 points, reflecting a 0.7% decrease from the previous week [5] Market Dynamics - The third batch of national TCM centralized procurement began in April 2025, with at least 19 provinces implementing results, involving 20 product groups and 174 selected drugs [6] - The procurement rules have been optimized to encourage reasonable pricing, but the completion rate remains low due to stricter controls on clinical medication [6] Investment Recommendations - The report maintains an "overweight" rating for the TCM industry, suggesting three main investment lines: 1. Price governance focusing on competitive products and companies with strong R&D capabilities [7] 2. Consumption recovery driven by macroeconomic improvement and aging population [8] 3. State-owned enterprise reform, which is expected to enhance performance and efficiency [9] Key Companies to Watch - Recommended companies include Zhaoli Pharmaceutical, Pianzihuang, and Shouxiangu, which are expected to benefit from centralized procurement and have strong brand recognition [9]

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-043 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 关于全资子公司完成国产保健食品备案的公告 | 产品名称 | 寿仙良品®破壁灵芝孢子粉片 | | --- | --- | | 保健功能 | 有助于增强免疫力 | | 备案号 | 食健备 G202533001731 | | 备案人 | 金华寿仙谷药业有限公司 | | 备案人地址 | 浙江省金华市武义县壶山街道商城路 10 号 | | 备案结论 | 按照《中华人民共和国食品安全法》《保健食品注册与备 | | | 案管理办法》等法律、规章的规定，予以备案。 | 上述产品备案成功不会对公司近期的生产经营产生重大影响，但有利于进一 步补充完善公司的产品品类，丰富公司的产品线，提升公司在保健食品领域的竞 争力，符合公司布局大健康产业的战略规划，为企业持续发展打下扩容基础。 特此公告。 浙江寿仙谷医药股份有限公司董事会 2025 年 6 月 12 日 本公司董事会及全体董事保证本公告内容不 ...

两位新生代掌门人收到"侨青创客"证书。杭州市侨联供图 中新网杭州6月8日电 (钱晨菲)近日，"侨青药创π·对话新生代掌门人"活动在位于浙江杭州的浙大城市学 院举行。该活动由杭州市侨联主办，浙大城市学院党委统战部、侨联、商学院承办，杭州市侨联青委 会、知名高校校友联盟协办。 浙大城市学院党委书记董悦介绍了浙大城市学院的基本情况和发展历程。他表示，本次活动是一场汇聚 侨智、共谋发展的盛会，到场嘉宾兼具海外学习经历和本土实践经验，融汇了全球视野与中国智慧。 杭州民生医药控股集团总裁竺昱祺、浙江寿仙谷医药股份有限公司总经理李振宇两位新生代掌门人围绕 海归创新、经营发展、人才引育等话题展开精彩对话，并就"企业是否缺人""有没有机会当老板"等问题 作出幽默解答。 杭州市侨联党组书记赵欣浩向在场的侨界青年和学子提出三点期许：一是勇当创新火种的传递者，以优 秀掌门人为榜样，发挥融通中外的独特优势，让更多源自杭州的创新成果闪耀世界；二是善作传递杭州 城市温度的代言人，善用语言文化优势，向世界讲述精彩的杭州故事、浙江故事，吸引更多全球顶尖人 才汇聚钱塘江畔；三是争当协作生态的共建者，借助"侨青荟"平台积极互动，在思想碰撞与务实合 ...

Core Insights - The opening of Yonghui Supermarket's Jiading Baolong store marks the sixth location in Shanghai adopting the "Pang Donglai" model, resulting in a significant increase in customer traffic and sales [1][5][35] - The store experienced a 318% year-on-year increase in customer flow and a 716% increase in sales during the first three days of operation [5][34] - The transformation of traditional supermarkets in Shanghai, such as the Century Lianhua Luban store, has also led to a resurgence in customer interest, indicating a broader trend in the retail sector [34][40] Group 1 - Yonghui's Jiading Baolong store has implemented a product structure that aligns with the "Pang Donglai" model, reducing the number of standard products from over 10,000 to around 8,000, with over 80% of the product structure now reflecting the "Pang Donglai" model [14][35] - The store introduced 67 self-owned brand products from "Pang Donglai," with a total of 8,868 items available after restructuring [11][14] - The bakery and ready-to-eat food sections have become particularly popular, with significant customer engagement observed in these areas [17][31] Group 2 - The store has adopted a limit purchase policy for certain "Pang Donglai" products, requiring customers to show an electronic membership code from the Yonghui app to make purchases [11][13] - The service quality at the Jiading store has been noted as a strong point, with various customer-friendly features implemented, although some staff members are still in training [24][28] - The store's layout has been optimized to enhance customer flow, separating high-traffic areas like the bakery and ready-to-eat food sections to improve shopping experience [14][31] Group 3 - The success of Yonghui's transformation is part of a larger trend in Shanghai's retail landscape, with other stores like Century Lianhua also reporting increased customer traffic following similar renovations [34][40] - The focus on community engagement and tailored services, such as the "潮银俱乐部" (潮银 Club) for the elderly, reflects a strategic shift towards meeting specific consumer needs [40][42] - The overall strategy involves reducing the number of low-efficiency, homogeneous products while enhancing the quality and variety of offerings, aiming to create a more engaging shopping experience [34][40]

Summary of Key Points Core Viewpoint - In May 2025, the total amount of stock reduction by directors, supervisors, and senior executives of listed companies in the Shanghai and Shenzhen stock markets reached approximately 2.186 billion yuan, resulting in a net reduction of 1.83 billion yuan after accounting for the total increase of about 356 million yuan [1][3]. Group 1: Stock Reduction - The total reduction amount in May 2025 was approximately 2.186 billion yuan, involving 153 companies [1][3]. - The computer industry had the highest reduction amount, approximately 412 million yuan, while the mechanical equipment and pharmaceutical industries followed with reductions of about 312 million yuan and 257 million yuan, respectively [11]. - The top three companies with the highest reduction amounts were: - Ruiming Technology: 302 million yuan [3][4] - Beijiete: 92 million yuan [3][4] - Bichuang Technology: 84 million yuan [3][4]. Group 2: Stock Increase - The total increase amount in May 2025 was approximately 356 million yuan, involving 48 companies [1][12]. - The food and beverage industry had the highest increase amount, approximately 141 million yuan, followed by the pharmaceutical industry with about 86 million yuan and the steel industry with approximately 53 million yuan [19]. - The top three companies with the highest increase amounts were: - Taoli Bread: 141 million yuan [12][16] - Shouxiangu: 73 million yuan [12][16] - Dazhong Mining: 53 million yuan [12][16].

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-042 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 关于全资子公司完成国产保健食品备案的公告 | 产品名称 | 寿仙良品®破壁灵芝孢子粉 | | --- | --- | | 保健功能 | 有助于增强免疫力 | | 备案号 | 食健备 G202533001633 | | 备案人 | 金华寿仙谷药业有限公司 | | 备案人地址 | 浙江省金华市武义县壶山街道商城路 10 号 | | 备案结论 | 按照《中华人民共和国食品安全法》《保健食品注册与备 | | | 案管理办法》等法律、规章的规定，予以备案。 | 上述产品备案成功不会对公司近期的生产经营产生重大影响，但有利于进一 步补充完善公司的产品品类，丰富公司的产品线，提升公司在保健食品领域的竞 争力，符合公司布局大健康产业的战略规划，为企业持续发展打下扩容基础。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确 ...

寿仙谷（603896）公告，近日全资子公司金华寿仙谷药业有限公司的"寿仙良品破壁灵芝孢子粉"产品完 成了国产保健食品备案工作，并获得浙江省市场监督管理局发放的国产保健食品备案凭证。产品名称为 寿仙良品破壁灵芝孢子粉，保健功能为有助于增强免疫力，备案号为食健备G202533001633，备案人金 华寿仙谷药业有限公司，地址为浙江省金华市武义县壶山街道商城路10号。备案结论为按照《中华人民 共和国食品安全法》《保健食品注册与备案管理办法》等法律、规章的规定，予以备案。上述产品备案 成功不会对公司近期的生产经营产生重大影响。 ...

Core Points - Zhejiang Shuxian Valley Pharmaceutical Co., Ltd. announced a cash dividend of 0.27 yuan per share for the fiscal year 2024, approved at the annual shareholders' meeting on May 13, 2025 [2][3][4] - The total cash dividend distribution amounts to approximately 53.53 million yuan, based on a total share capital of 198,243,911 shares [4] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the record date [3][4] Distribution Plan - The cash dividend distribution is based on the company's total share capital as of the record date, with each share receiving a cash dividend of 0.27 yuan (before tax) [4] - The distribution will be managed by the China Securities Depository and Clearing Corporation, with shareholders who have completed designated transactions able to receive their dividends on the payment date [6][8] Taxation Details - For individual shareholders holding unrestricted shares, no income tax will be withheld at the time of dividend distribution; tax will be calculated based on the holding period when shares are sold [9] - For shares held for less than one month, the tax rate is 20%; for one month to one year, the tax rate is 10%; and for over one year, dividends are exempt from personal income tax [9] - For foreign institutional investors, a 10% withholding tax will apply, resulting in a net dividend of 0.243 yuan per share [10] Convertible Bond Adjustment - The company announced an adjustment to the conversion price of its convertible bonds ("Shu 22 Convertible Bonds") due to the dividend distribution, changing from 37.11 yuan to 36.84 yuan per share [19][21] - The adjustment will take effect on June 6, 2025, with the bonds being suspended from conversion from May 28 to June 5, 2025 [21]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-040 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.27元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/5 | － | 2025/6/6 | 2025/6/6 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 13 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3 ...